Skip to main content
Journal cover image

Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.

Publication ,  Journal Article
Mitra, AK; Thummel, KE; Kalhorn, TF; Kharasch, ED; Unadkat, JD; Slattery, JT
Published in: Clin Pharmacol Ther
November 1995

Dapsone toxicity is putatively initiated by formation of a hydroxylamine metabolite by cytochromes P450. In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM). Troleandomycin (40 mumol/L) inhibited hydroxylamine formation at 100 mumol/L dapsone by 50%; diethyldithiocarbamate (150 mumol/L) and tolbutamide (400 mumol/L) inhibited at 5 mumol/L dapsone by 50% and 20%, respectively, suggesting that the low-affinity isozyme is CYP3A4 and the high-affinity isozymes are 2E1 and 2C. Disulfiram, 500 mg, 18 hours before a 100 mg oral dose of dapsone in healthy volunteers, diminished area under the hydroxylamine plasma concentration-time curve by 65%, apparent formation clearance of the hydroxylamine by 71%, and clearance of dapsone by 26%. Disulfiram produced a 78% lower concentration of methemoglobin 8 hours after dapsone.

Duke Scholars

Published In

Clin Pharmacol Ther

DOI

ISSN

0009-9236

Publication Date

November 1995

Volume

58

Issue

5

Start / End Page

556 / 566

Location

United States

Related Subject Headings

  • Troleandomycin
  • Pharmacology & Pharmacy
  • Oxidoreductases, N-Demethylating
  • Microsomes, Liver
  • Male
  • Leprostatic Agents
  • Hydroxylation
  • Humans
  • Female
  • Drug Interactions
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mitra, A. K., Thummel, K. E., Kalhorn, T. F., Kharasch, E. D., Unadkat, J. D., & Slattery, J. T. (1995). Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther, 58(5), 556–566. https://doi.org/10.1016/0009-9236(95)90176-0
Mitra, A. K., K. E. Thummel, T. F. Kalhorn, E. D. Kharasch, J. D. Unadkat, and J. T. Slattery. “Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.Clin Pharmacol Ther 58, no. 5 (November 1995): 556–66. https://doi.org/10.1016/0009-9236(95)90176-0.
Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther. 1995 Nov;58(5):556–66.
Mitra, A. K., et al. “Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.Clin Pharmacol Ther, vol. 58, no. 5, Nov. 1995, pp. 556–66. Pubmed, doi:10.1016/0009-9236(95)90176-0.
Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther. 1995 Nov;58(5):556–566.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

ISSN

0009-9236

Publication Date

November 1995

Volume

58

Issue

5

Start / End Page

556 / 566

Location

United States

Related Subject Headings

  • Troleandomycin
  • Pharmacology & Pharmacy
  • Oxidoreductases, N-Demethylating
  • Microsomes, Liver
  • Male
  • Leprostatic Agents
  • Hydroxylation
  • Humans
  • Female
  • Drug Interactions